CDMOs
WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects
BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns
BIOSECURE Act: Navigating Industry Implications and Future Directions
BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience
Streamlining Drug Development: The Power of Phase-Appropriate Technology Transfers
Technology Transfer, Phase-Appropriate Technology Transfer, Drug Development, Pharmaceutical Manufacturing, CDMOs (Contract Development and Manufacturing Organizations), Regulatory Compliance, Innovation in Drug Development
CDMO Leaders Unite for Turn-key Drug Production
Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.
Lonza Acquires Roche’s Massive Biologics Production Facility in Vacaville, California for $1.2 Billion
Lonza, Roche, Genentech, Biologics Manufacturing Site, Vacaville/ California, $1.2 Billion Deal, Large-Scale Commercial Mammalian Products, Expansion Plans ($561 Million), Capacity Utilization, Contract Development and Manufacturing Organizations (CDMOs), Global Biologics Market Growth